VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, handed the prestigious Ophthalmology Star Awards 2024 (OSA) to its owners during the Satellite Symposium at the ESCRS 2024 Congress in Barcelona.
Eye Drop Company Faces FDA Scrutiny Again Over Unapproved ProductsSep 19, 2024The FDA has issued a warning letter to the Regenerative Processing Plant, manufacturer of Regener-Eyes Pro and Lite eye drops, for marketing unapproved products claiming to treat dry eyes.
Maestro®: The Sinusoidal IOLSep 18, 2024VSY Biotechnology introduced the Maestro® Sinusoidal IOL at ESCRS 2024, featuring SVT. This innovative trifocal lens enhances visual acuity, contrast sensitivity, and light transmission, offering a cutting-edge solution for presbyopia management.
BlueRock Therapeutics Receives FDA Clearance for OpCT-001 IND ApplicationSep 05, 2924BlueRock Therapeutics, a subsidiary of Bayer, announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases.
Rethinking Dry Eye Diagnosis in Patients Unresponsive to TreatmentOct 25, 2024Many conditions can mimic dry eye disease (DED), leading to misdiagnoses and ineffective treatments, warned Vatinee Y. Bunya, MD, MSCE, during a presentation at Cornea Subspecialty Day at the American Academy of Ophthalmology meeting.
Nicotine's Potential in Myopia Control: Animal Research FindingsSep 27, 2024Researchers led by Dr. Kate Thomson from the University of Canberra have found that nicotine, when administered either as an intravitreal injection or topical eye drop, significantly inhibited the development of FDM and LIM in chicks.
Lamprey's Eye Disease: Separating Fact from FictionSep 30, 2024Lamprey Eye Disease, also known as "Lamprey Disease," is a hoax that has been circulating on the internet for several years. The hoax claims that a parasitic fish known as the lamprey is responsible for a disease that can cause blindness in humans.